Facing Our Risk of Cancer Empowered: FORCE

About Facing Our Risk of Cancer Empowered: FORCE

Facing Our Risk of Cancer Empowered: FORCE operates in the Non-Profit / Society space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-07-02
  Facing Our Risk Of Cancer Empowered Force appoints new Chief Medical Officer ahead of pivotal trial
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• BioPharma Reporter · 2026-08-25
  Facing Our Risk Of Cancer Empowered Force signs supply agreement to support late-stage trials
  The work builds on more than a decade of radiochemistry collaboration.
• Reuters Health · 2026-01-16
  Facing Our Risk Of Cancer Empowered Force expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-06-27
  Facing Our Risk Of Cancer Empowered Force announces Phase II readout for lead theranostic candidate
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• Nuclear Medicine Today · 2026-07-02
  Facing Our Risk Of Cancer Empowered Force files IND for next-generation PSMA-targeted agent
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.